Literature DB >> 24317323

Functional selectivity at GPCRs: new opportunities in psychiatric drug discovery.

Steven D Chang1, Michael R Bruchas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24317323      PMCID： PMC3857652          DOI： 10.1038/npp.2013.205

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  7 in total

1.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 2.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

3.  Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.

Authors:  Michael R Bruchas; Abigail G Schindler; Haripriya Shankar; Daniel I Messinger; Mayumi Miyatake; Benjamin B Land; Julia C Lemos; Catherine E Hagan; John F Neumaier; Albert Quintana; Richard D Palmiter; Charles Chavkin
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

Review 4.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact.

Authors:  Terry Kenakin; Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2012-02-15       Impact factor: 84.694

Review 5.  Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors:  Michael R Bruchas; Charles Chavkin
Journal:  Psychopharmacology (Berl)       Date:  2010-04-17       Impact factor: 4.530

6.  Structural features for functional selectivity at serotonin receptors.

Authors:  Daniel Wacker; Chong Wang; Vsevolod Katritch; Gye Won Han; Xi-Ping Huang; Eyal Vardy; John D McCorvy; Yi Jiang; Meihua Chu; Fai Yiu Siu; Wei Liu; H Eric Xu; Vadim Cherezov; Bryan L Roth; Raymond C Stevens
Journal:  Science       Date:  2013-03-21       Impact factor: 47.728

7.  Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.

Authors:  Nikhil M Urs; Joshua C Snyder; Jacob P R Jacobsen; Sean M Peterson; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205
  7 in total
  7 in total

1.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

2.  Sequence-Specific Regulation of Endocytic Lifetimes Modulates Arrestin-Mediated Signaling at the µ Opioid Receptor.

Authors:  Zara Y Weinberg; Amanda S Zajac; Tiffany Phan; Daniel J Shiwarski; Manojkumar A Puthenveedu
Journal:  Mol Pharmacol       Date:  2017-02-02       Impact factor: 4.436

3.  Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.

Authors:  Steven D Chang; S Wayne Mascarella; Skylar M Spangler; Vsevolod V Gurevich; Hernan A Navarro; F Ivy Carroll; Michael R Bruchas
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

Review 4.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

5.  Full and Partial Agonism of a Designed Enzyme Switch.

Authors:  S Jimmy Budiardjo; Timothy J Licknack; Michael B Cory; Dora Kapros; Anuradha Roy; Scott Lovell; Justin Douglas; John Karanicolas
Journal:  ACS Synth Biol       Date:  2016-07-22       Impact factor: 5.110

Review 6.  The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors.

Authors:  Rafael Franco; Paula Morales; Gemma Navarro; Nadine Jagerovic; Irene Reyes-Resina
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

7.  Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor.

Authors:  Francheska Delgado-Peraza; Kwang H Ahn; Carlos Nogueras-Ortiz; Imran N Mungrue; Ken Mackie; Debra A Kendall; Guillermo A Yudowski
Journal:  Mol Pharmacol       Date:  2016-03-23       Impact factor: 4.436
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.